Bimekizumab – an IL-17A and IL-17F inhibitor – outdid both placebo and IL-12/IL-23 blocker Stelara (ustekinumab ... additional data in psoriasis, psoriatic arthritis and ankylosing spondylitis ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Celltrion’s Steqeyma, a biosimilar that references Johnson & Johnson’s blockbuster monoclonal antibody Stelara ... can treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ...

Stelara (ustekinumab) was launched almost 15 years ago as a treatment for psoriasis and in the interim has picked up additional indications in psoriatic arthritis, Crohn’s disease, and ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Stelara (ustekinumab ... But thanks to advances in PsA treatments, most disease complications can be avoided. Juvenile psoriatic arthritis is a type of juvenile idiopathic arthritis.

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse cardiovascular and venous thromboembolic events compared with those treated ...